Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;79(10):1037-1051.
doi: 10.1007/s40265-019-01139-4.

Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease

Ye Zhao  1 , Nicolas Dzamko  2
Affiliations
Review

Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease

Ye Zhao et al. Drugs. 2019 Jul.

Abstract

Kinase activating missense mutations in leucine-rich repeat kinase 2 (LRRK2) are pathogenically linked to neurodegenerative Parkinson's disease (PD). Over the past decade, substantial effort has been devoted to the development of potent and selective small molecule inhibitors of LRRK2, as well as their preclinical testing across different Parkinson's disease models. This review outlines the genetic and biochemical evidence that pathogenic missense mutations increase LRRK2 kinase activity, which in turn provides the rationale for the development of small molecule inhibitors as potential PD therapeutics. An overview of progress in the development of LRRK2 inhibitors is provided, which in particular indicates that highly selective and potent compounds capable of clinical utility have been developed. We outline evidence from rodent- and human-induced pluripotent stem cell models that support a pathogenic role for LRRK2 kinase activity, and review the substantial experiments aimed at evaluating the safety of LRRK2 inhibitors. We address challenges still to overcome in the translational therapeutic pipeline, including biomarker development and clinical trial strategies, and finally outline the potential utility of LRRK2 inhibitors for other genetic forms of PD and ultimately sporadic PD. Collective evidence supports the ongoing clinical translation of LRRK2 inhibitors as a therapeutic intervention for PD is greatly needed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Invest. 2002 May;109(9):1215-21 - PubMed
    1. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 - PubMed
    1. Neuron. 2003 Sep 11;39(6):889-909 - PubMed
    1. Neurology. 2004 May 11;62(9):1619-22 - PubMed
    1. Ann Neurol. 2004 Oct;56(4):532-9 - PubMed

MeSH terms

Substances

LinkOut - more resources